Comprehensive Stock Comparison
Compare CytomX Therapeutics, Inc. (CTMX) vs Apple Inc. (AAPL) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Growth | CTMX | 36.4% revenue growth vs AAPL's 6.4% |
| Value | CTMX | Lower P/E (14.1x vs 31.1x) |
| Quality / Margins | AAPL | 27.0% net margin vs CTMX's 24.7% |
| Stability / Safety | CTMX | Beta 1.08 vs AAPL's 1.28 |
| Dividends | AAPL | 0.4% yield; 14-year raise streak; CTMX pays no meaningful dividend |
| Momentum (1Y) | CTMX | +6.9% vs AAPL's +9.7% |
| Efficiency (ROA) | AAPL | 31.1% ROA vs CTMX's 17.7% |
Who Each Stock Is For
Income & stability
Growth exposure
Long-term compounding (10Y)
Sleep-well-at-night portfolio
Defensive / Recession hedge
Business Model
What each company does and how it makes money
CytomX Therapeutics is an oncology-focused biopharmaceutical company that develops conditionally activated antibody therapeutics using its proprietary Probody technology platform. It generates revenue primarily through strategic collaborations and licensing deals with major pharmaceutical partners — including AbbVie, Amgen, and Bristol-Myers Squibb — which provide upfront payments, milestone payments, and potential future royalties on any commercialized products. The company's key competitive advantage is its Probody platform technology, which creates conditionally activated therapeutics that remain inactive until they reach the tumor microenvironment, potentially improving safety and efficacy compared to traditional antibody therapies.
Apple is a technology giant that designs and sells premium consumer electronics — most famously the iPhone — along with related software and services. It generates revenue primarily from hardware sales (roughly 80% of total) and a fast-growing services segment (around 20%) that includes the App Store, subscriptions, and licensing. Its key competitive advantage is a powerful ecosystem that locks users into its hardware, software, and services through seamless integration and high switching costs.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
AAPL leads in 3 of 6 categories (Financial Metrics, Profitability & Efficiency). CTMX leads in 2 (Valuation Metrics, Total Returns). 1 tied.
Financial Metrics (TTM)
AAPL is the larger business by revenue, generating $435.6B annually — 3833.6x CTMX's $114M. Profitability is closely matched — net margins range from 27.0% (AAPL) to 24.7% (CTMX). On growth, AAPL holds the edge at +15.7% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | CTMXCytomX Therapeuti… | AAPLApple Inc. |
|---|---|---|
| RevenueTrailing 12 months | $114M | $435.6B |
| EBITDAEarnings before interest/tax | $25M | $152.9B |
| Net IncomeAfter-tax profit | $28M | $117.8B |
| Free Cash FlowCash after capex | -$72M | $123.3B |
| Gross MarginGross profit ÷ Revenue | +100.0% | +47.3% |
| Operating MarginEBIT ÷ Revenue | +20.5% | +32.4% |
| Net MarginNet income ÷ Revenue | +24.7% | +27.0% |
| FCF MarginFCF ÷ Revenue | -63.7% | +28.3% |
| Rev. Growth (YoY)Latest quarter vs prior year | -82.2% | +15.7% |
| EPS Growth (YoY)Latest quarter vs prior year | -2.3% | +18.3% |
Valuation Metrics
At 14.1x trailing earnings, CTMX trades at a 60% valuation discount to AAPL's 35.4x P/E. On an enterprise value basis, CTMX's 15.0x EV/EBITDA is more attractive than AAPL's 27.5x.
| Metric | CTMXCytomX Therapeuti… | AAPLApple Inc. |
|---|---|---|
| Market CapShares × price | $430M | $3.88T |
| Enterprise ValueMkt cap + debt − cash | $401M | $3.97T |
| Trailing P/EPrice ÷ TTM EPS | 14.13x | 35.41x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 31.15x |
| PEG RatioP/E ÷ EPS growth rate | — | 1.98x |
| EV / EBITDAEnterprise value multiple | 15.00x | 27.45x |
| Price / SalesMarket cap ÷ Revenue | 3.11x | 9.33x |
| Price / BookPrice ÷ Book value/share | — | 53.76x |
| Price / FCFMarket cap ÷ FCF | — | 39.33x |
Profitability & Efficiency
AAPL delivers a 133.5% return on equity — every $100 of shareholder capital generates $134 in annual profit, vs $26 for CTMX. On the Piotroski fundamental quality scale (0–9), AAPL scores 7/9 vs CTMX's 4/9, reflecting strong financial health.
| Metric | CTMXCytomX Therapeuti… | AAPLApple Inc. |
|---|---|---|
| ROE (TTM)Return on equity | +26.1% | +133.5% |
| ROA (TTM)Return on assets | +17.7% | +31.1% |
| ROICReturn on invested capital | — | +64.5% |
| ROCEReturn on capital employed | +62.0% | +69.6% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 7 |
| Debt / EquityFinancial leverage | — | 1.67x |
| Net DebtTotal debt minus cash | -$29M | $89.7B |
| Cash & Equiv.Liquid assets | $38M | $33.5B |
| Total DebtShort + long-term debt | $9M | $123.3B |
| Interest CoverageEBIT ÷ Interest expense | — | — |
Total Returns (with DRIP)
A $10,000 investment in AAPL five years ago would be worth $21,049 today (with dividends reinvested), compared to $6,355 for CTMX. Over the past 12 months, CTMX leads with a +693.0% total return vs AAPL's +9.7%. The 3-year compound annual growth rate (CAGR) favors CTMX at 35.7% vs AAPL's 21.9% — a key indicator of consistent wealth creation.
| Metric | CTMXCytomX Therapeuti… | AAPLApple Inc. |
|---|---|---|
| YTD ReturnYear-to-date | +26.4% | -2.4% |
| 1-Year ReturnPast 12 months | +693.0% | +9.7% |
| 3-Year ReturnCumulative with dividends | +149.8% | +81.2% |
| 5-Year ReturnCumulative with dividends | -36.4% | +110.5% |
| 10-Year ReturnCumulative with dividends | -58.4% | +1027.4% |
| CAGR (3Y)Annualised 3-year return | +35.7% | +21.9% |
Risk & Volatility
CTMX is the less volatile stock with a 1.08 beta — it tends to amplify market swings less than AAPL's 1.28 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. AAPL currently trades 91.5% from its 52-week high vs CTMX's 84.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | CTMXCytomX Therapeuti… | AAPLApple Inc. |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.08x | 1.28x |
| 52-Week HighHighest price in past year | $6.35 | $288.61 |
| 52-Week LowLowest price in past year | $0.40 | $169.21 |
| % of 52W HighCurrent price vs 52-week peak | +84.6% | +91.5% |
| RSI (14)Momentum oscillator 0–100 | 52.0 | 57.5 |
| Avg Volume (50D)Average daily shares traded | 2.6M | 40.9M |
Analyst Outlook
Wall Street rates CTMX as "Buy" and AAPL as "Buy". Consensus price targets imply 86.2% upside for CTMX (target: $10) vs 14.7% for AAPL (target: $303). AAPL is the only dividend payer here at 0.39% yield — a key consideration for income-focused portfolios.
| Metric | CTMXCytomX Therapeuti… | AAPLApple Inc. |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $10.00 | $303.11 |
| # AnalystsCovering analysts | 21 | 109 |
| Dividend YieldAnnual dividend ÷ price | — | +0.4% |
| Dividend StreakConsecutive years of raises | 1 | 14 |
| Dividend / ShareAnnual DPS | — | $1.03 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +2.3% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Feb 20 | Feb 26 | Change |
|---|---|---|---|
| CytomX Therapeutics… (CTMX) | 100 | 91.03 | -9.0% |
| Apple Inc. (AAPL) | 100 | 395.1 | +295.1% |
Apple Inc. (AAPL) returned +110% over 5 years vs CytomX Therapeutics… (CTMX)'s -36%. A $10,000 investment in AAPL 5 years ago would be worth $21,049 today (including dividends reinvested).
Chart 2Revenue Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| CytomX Therapeutics… (CTMX) | $15M | $138M | +818.1% |
| Apple Inc. (AAPL) | $215.6B | $416.2B | +93.0% |
Apple Inc.'s revenue grew from $215.6B (2016) to $416.2B (2025) — a 7.6% CAGR.
Chart 3Net Margin Trend — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| CytomX Therapeutics… (CTMX) | -3.9% | 23.1% | +689.4% |
| Apple Inc. (AAPL) | 21.2% | 26.9% | +27.0% |
Apple Inc.'s net margin went from 21% (2016) to 27% (2025).
Chart 4P/E Ratio History — 9 Years
| Stock | 2017 | 2025 | Change |
|---|---|---|---|
| Apple Inc. (AAPL) | 18.4 | 36.4 | +97.8% |
Apple Inc. has traded in a 13x–41x P/E range over 9 years; current trailing P/E is ~35x.
Chart 5EPS Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| CytomX Therapeutics… (CTMX) | -1.63 | 0.38 | +123.3% |
| Apple Inc. (AAPL) | 2.08 | 7.46 | +258.7% |
Apple Inc.'s EPS grew from $2.08 (2016) to $7.46 (2025) — a 15% CAGR.
Chart 6Free Cash Flow — 5 Years
CytomX Therapeutics, Inc. generated $-87M FCF in 2024 (+28% vs 2021). Apple Inc. generated $99B FCF in 2025 (+6% vs 2021).
CTMX vs AAPL: Frequently Asked Questions
9 questions · data-driven answers · updated daily
01Is CTMX or AAPL a better buy right now?
CytomX Therapeutics, Inc. (CTMX) offers the better valuation at 14.1x trailing P/E, making it the more compelling value choice. Analysts rate CytomX Therapeutics, Inc. (CTMX) a "Buy" — based on 21 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — CTMX or AAPL?
On trailing P/E, CytomX Therapeutics, Inc. (CTMX) is the cheapest at 14.1x versus Apple Inc. at 35.4x.
03Which is the better long-term investment — CTMX or AAPL?
Over the past 5 years, Apple Inc. (AAPL) delivered a total return of +110.5%, compared to -36.4% for CytomX Therapeutics, Inc. (CTMX). A $10,000 investment in AAPL five years ago would be worth approximately $21K today (assuming dividends reinvested). Over 10 years, the gap is even starker: AAPL returned +1027% versus CTMX's -58.4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — CTMX or AAPL?
By beta (market sensitivity over 5 years), CytomX Therapeutics, Inc. (CTMX) is the lower-risk stock at 1.08β versus Apple Inc.'s 1.28β — meaning AAPL is approximately 19% more volatile than CTMX relative to the S&P 500.
05Which has better profit margins — CTMX or AAPL?
Apple Inc. (AAPL) is the more profitable company, earning 26.9% net margin versus 23.1% for CytomX Therapeutics, Inc. — meaning it keeps 26.9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AAPL leads at 32.0% versus 18.1% for CTMX. At the gross margin level — before operating expenses — CTMX leads at 100.0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is CTMX or AAPL more undervalued right now?
Analyst consensus price targets imply the most upside for CTMX: 86.2% to $10.00.
07Which pays a better dividend — CTMX or AAPL?
In this comparison, AAPL (0.4% yield) pays a dividend. CTMX does not pay a meaningful dividend and should not be held primarily for income.
08Is CTMX or AAPL better for a retirement portfolio?
For long-horizon retirement investors, Apple Inc. (AAPL) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1.28), +1027% 10Y return). Both have compounded well over 10 years (AAPL: +1027%, CTMX: -58.4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between CTMX and AAPL?
These companies operate in different sectors (CTMX (Healthcare) and AAPL (Technology)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced. In terms of investment character: CTMX is a small-cap deep-value stock; AAPL is a mega-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.